Abeliovich Asa 4
4 · Prevail Therapeutics Inc. · Filed Dec 31, 2020
Insider Transaction Report
Form 4
Abeliovich Asa
DirectorPresident & CEO10% Owner
Transactions
- Exercise/Conversion
Common Stock
2020-12-30$10.26/sh+120,537$1,236,710→ 2,474,793 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-12-30−5,256→ 1,329,219 totalExercise: $0.18Exp: 2028-03-05→ Common Stock (5,256 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2020-12-30−120,537→ 178,681 totalExercise: $10.26Exp: 2029-04-24→ Common Stock (120,537 underlying) - Exercise/Conversion
Common Stock
2020-12-30$0.18/sh+5,256$946→ 2,354,256 total - Tax Payment
Common Stock
2020-12-30$23.02/sh−89,037$2,049,632→ 2,385,756 total
Footnotes (2)
- [F1]25% of the total number of shares underlying the option vested and became exercisable on March 7, 2019 and an additional 1/48th of the total number of shares underlying the option shall vest and become exercisable on the first day of each of the thirty-six (36) consecutive months thereafter subject, in all cases, to the Reporting Person providing continuous service with the Issuer on each such date.
- [F2]25% of the total number of shares underlying the option shall vest and become exercisable on April 24, 2020 and an additional 1/48th of the total number of shares underlying the option shall vest and become exercisable on the same date of each of the thirty-six (36) consecutive months thereafter subject, in all cases, to the Reporting Person providing continuous service with the Issuer on each such date.